Liquid composition containing non-menthol cooling agent and gel former for therapy of respiratory symptom

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely represents a method for the therapy of respiratory symptom. The method involves administering a liquid composition containing a gel former and/or a mucoactive polymer, a non-menthol cooling substance; and contacting the oral mucosa with the liquid composition. The invention also describes liquid compositions applicable in the method for the therapy of a respiratory disease.

EFFECT: implementing the method provides improving the cooling properties of the cooling agent N-(4-cyanomethylphenyl)-n-menthane carboxamide in the liquid composition by combining the non-menthol cooling substance with the gel former.

14 cl, 2 tbl, 5 dwg

 

AREA of TECHNOLOGY

The present invention relates to a method for the treatment of respiratory symptom, comprising administering a liquid composition. The invention further relates to liquid compositions described here.

Prior art

Currently consumers seeking to alleviate respiratory symptoms (e.g., symptomatic relief, temporary or permanent), including relief from sore throat, nasopharyngeal leaking or common cold symptoms, experience a delay between the time when consumers are taking oral products acting on the respiratory system, and the time when they begin to experience relief of symptoms of colds. This is because most of the products that affect the respiratory tract, contain active substances which, for the manifestation of its action must first become bioavailable in the bloodstream. Thus, the consumer must wait for the suction of the product to obtain any weakening of symptoms.

As an example, cough syrups often contain active substances that must first enter the bloodstream, often to relieve coughs is approximately 30 minutes; thus, the consumer does not arise instantaneous or long-acting sensory/olfactory FOTS�of Iate, designed to create a sense of "feel better" during the delay of therapeutic action.

The present invention provides a liquid composition that provides immediate and continuing for a long time, the cooling sensation, the delivery of which is by increasing deposits in the oral mucosa, such as mouth and throat;

the composition includes a system that is conducive to increased contact time with the mucous membrane of the oral cavity due to the synergy of polymers included in the composition, and the type of cooling substances. Additionally, the liquid composition may be used to enhance and/or modulate the cooling action of the substances included in the composition, which affects the mucous membrane of the oral cavity and provides a cooling sensation that lasts for more than 10 minutes and results in a more rapid manifestation of the consumer reaction to "improve the experience".

Summary of the INVENTION

One embodiment relates to a method of strengthening the overall cooling sensation on the mucous membrane of the oral cavity, comprising the steps of: introducing a liquid composition comprising: 1) a thickener; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling agent; and introducing into contact with mucous sheaths from her bouti�and oral cavity with a liquid composition.

Additional embodiment, furthermore, relates to a method of increasing the time of contact between the liquid composition and the mucous membrane of the oral cavity to enhance the overall cooling sensation comprising the stage of introduction of the liquid composition comprising: 1) a thickener; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

One embodiment relates to a method of strengthening the overall cooling sensation on the mucous membrane of the oral cavity, comprising the steps of: introducing a liquid composition containing: 1) mucoadhesive polymer; 2) optionally a thickener; and (3) nematalosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

Additional embodiment, furthermore, relates to a method for amplifying and/or modulating activity of one or more nematology cooling substances included in the liquid composition, which includes stages: preparation of a liquid composition comprising: 1) a thickener; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling substance; introducing the liquid composition; introduction to the contact of the mucous membranes of the oral cavity with a liquid composition; wherein the liquid composition creates in contact with the mucous bolocco� oral, long-acting cooling sensation, lasting more than 10 minutes.

Additional embodiment, furthermore, relates to a method of providing a soothing effect to the user, feeling cold symptoms comprising steps of: introducing a liquid composition comprising: 1) a thickener; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling substance; introduction to the contact of the liquid composition to the mucosa of the oral cavity of the user; and an overall cooling sensation on the mucous membrane of the oral cavity of the user.

Additional embodiment, furthermore, relates to a liquid composition, creating a cooling sensation on the mucous membrane of the oral cavity of a user comprising: a thickener; mucoadhesive polymer; and N-(4-cyanomethylene)-p-metacarbonate; where the composition provides long-acting cooling sensation lasting more than 10 minutes.

Additional embodiment, furthermore, relates to a method of increasing the time of contact between the liquid composition and the mucous membrane of the oral cavity to enhance the overall cooling sensation comprising the stage of introduction of a liquid composition containing: 1) mucoadhesive polymer; 2) optionally a thickener; and (3) nematalosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

To�additional embodiment, furthermore, relates to a method of amplifying and/or modulating activity of one or more nematology cooling substances included in the liquid compositions, which includes stages: preparation of a liquid composition containing: 1) mucoadhesive polymer; 2) optionally a thickener; and (3) nematalosa cooling substance; introducing the liquid composition; introduction to the contact of the mucous membranes of the oral cavity with a liquid composition; wherein the liquid composition creates in contact with the mucous membrane of the mouth, long-acting cooling sensation lasting more than 10 minutes.

Additional embodiment, furthermore, relates to a method of providing a cushioning effect for the user who perceives the symptoms of a cold, which comprises the steps of: introducing a liquid composition containing: 1) mucoadhesive polymer; 2) optionally a thickener; 3) nematalosa cooling agent; and introduction to the contact of the liquid composition to the mucosa of the oral cavity of the user; and an overall cooling sensation on the mucous membrane of the oral cavity of the user.

BRIEF description of the DRAWINGS

Fig.1 is a graph of the perceived thickness of the product;

Fig.2 is a graph of the perceived intensity of a cooling sensation in the mouth as a function of time;

Fig.3 represents Soboh� graph of the perceived intensity of a cooling sensation in the throat as a function of time;

Fig.4 is a graph of the perceived intensity of the overall cooling sensation as a function of time; and

Fig.5 is a graph of the perceived intensity of a cushioning effect as a function of time.

DETAILED DESCRIPTION of the INVENTION

The present invention relates to a method of treatment of respiratory symptom, comprising the stage of introduction of a liquid composition containing:

1) thickening; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

These and other features of the compositions and methods of the present invention, as well as many optional ingredients suitable for use in the present invention, described in detail below.

The term "total cooling sensation", used here value means the number of sensations of heat, cold, numbness and tingling, penetrating into the tissue of the mucous membranes of the mouth, throat and thoracic cavity.

The term "liquid composition", used here, the value applies to the composition in a form suitable for delivery to the needy in the mammal via the oral cavity, mouth, throat, nasal passage, or combinations thereof. The liquid composition may be in a form suitable for direct delivery to the mucosa of the cavity� mouth.

The term "mucous membrane of the mouth", used here, the value applies to the mouth and throat. Such compositions optionally can be delivered using the delivery devices selected from the droppers, pumps, sprayers, droppers, spoons, cups, squeeze packets, devices for vstraivaniya" (power shots) and other containers, devices, packages, or equipment and their combinations.

All weights, measurements and concentrations shown here, measured at 25°C for compositions in General, unless otherwise indicated.

All percentages, parts and ratios, used here the value is given by weight of the overall composition, unless otherwise indicated. All these weight related to listed ingredients are based on the level of content of the active substance, and therefore, do not include solvents or by-products that may be included in commercially available materials, unless otherwise indicated.

Composition, preparations and methods of the present invention can include, consist of, or consist essentially of, the essential elements and features of the invention described here, as well as any additional or optional ingredients, components or characteristics described here or otherwise suitable for use in compositions intended for use or apotre�ing mammals, preferably, for use or used by people.

The methods of the present invention

The present invention described here relates to a method for therapy of respiratory symptom in a mammal (such as man) in need of such therapy, including any of the following: increased cooling sensation on the mucous membrane of the mouth; increased contact time between the liquid composition and the mucous membrane of the mouth; modulating the activity of one or more cooling substances; and providing a cushioning effect to a mammal, sensing a symptom of the common cold, for example, pain, dryness and other discomfort in the throat or in other parts of the mucous membrane of the oral cavity.

In one embodiment, the methods of the present invention provide a means to enhance the overall cooling sensation on the mucous membrane of the mouth. The methods include the introduction of liquid composition to ensure the effect of formation of the coating on the mucous membrane of the mouth, which increases the contact time of the composition to the mucosa of the oral cavity and provides immediate and long-acting cooling sensation. This increased cooling sensation caused by the presence of synergy between the different ingredients contained in the liquid composition, such to�to, for example, the selected thickeners, mucoadhesive polymers or nematology cooling substances.

Used here the value "gain" and/or "providing relief", in relation to a cooling feeling, means that the introduction of these compositions acting on the respiratory system, creates an immediate or long and lingering sense of coolness, which provides a feeling of mitigating, alleviating, suppressing or reducing one or more of respiratory symptoms in a mammal.

In an additional embodiment, the present invention relates to methods of strengthening the common cooling sensation on the mucous membrane of the oral cavity, comprising the steps of: introducing a liquid composition comprising: a thickener and/or mucoadhesive polymer; and nematolosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

In an additional embodiment, the invention relates to a method of increasing the time of contact between the liquid composition and the mucous membrane of the oral cavity to enhance the overall cooling sensation comprising the stage of introduction of a liquid composition containing a thickener and/or mucoadhesive polymer; and nematolosa cooling agent; and introducing into contact with mucous membranes of the oral cavity with a liquid composition.

In additional �the Ariant of execution, the present invention relates to a method of modulating activity of one or more nematology cooling substances included in the liquid composition, which includes stages: preparation of a liquid composition containing a thickener and/or mucoadhesive polymer; and nematolosa cooling substance; introducing the composition acting on the respiratory tract; and introduction to the contact of the mucous membranes of the oral cavity with a liquid composition; wherein the liquid composition creates in contact with the mucous membrane of the mouth, long-acting cooling sensation, lasting more than 10 minutes. The term "modulate" is used here to denote the modification of the effect of one or more nematology cooling substances contained in a liquid composition, which helps to mitigate tart, pungent, acrid or bitter feelings generated by a cooling substance (substances), including, without limitation, increasing its activity, with the aim of ensuring long-acting cooling sensation lasting more than 10 minutes, alternatively, more than 20 minutes after injection, an alternative, more 30 minutes after injection, an alternative, more 45 minutes after injection, an alternative, more than 60 minutes after injection.

In an additional embodiment, the present invention relates to a method of providing a cushioning EF�EKTA to a mammal, feeling cold symptoms comprising steps of: introducing a liquid composition comprising: 1) a thickener; 2) mucoadhesive polymer; 3) nematalosa cooling substance; introduction to the contact of the liquid composition to the mucosa of the oral cavity of a mammal; and an overall cooling sensation on the mucous membrane of the oral cavity of the user.

Used here meaning the term "oral administration" and/or "introduction" to the person/mammal means that the person/mammal takes in or gives instructions to take orally (by swallowing, spraying or any other means) one or more liquid compositions of the present invention. Person/mammal may be instructed to deliver the liquid composition to the place of a human/mammal intends to expose therapy, for example, the mucous membrane of the mouth. Person/mammal may be instructed to ingest the composition and such description and or delivery can instruct and/or inform the person that the application of the composition can provide and/or will provide a sense of relief respiratory symptom (e.g., symptomatic relief, whether temporary or permanent) for example, relief from sore throat. Relief can be instant� or delayed. For example, such an instruction may be oral indication (e.g., through oral instruction from, for example, physician, pharmacist or other professional in the medical field), radio or television message (e.g., advertisement), or written direction (e.g., in the form of written instructions, for example, physician, pharmacist or other specialist in the field of medicine (e.g., recipes), specialized trade organization (eg. with the help of promotional brochures, or other means of guidance), written informational messages (e.g., in the Internet, e-mail or other computer sources of information), and/or packaging associated with the composition (e.g., the label on the device for delivery containing composition). Used here the value "written" means using words, pictures, symbols and/or other visible or perceived tactile descriptors. Such information should contain the exact used here, the terms, for example, "respiratory", "symptom" or "mammal", and within the scope of the present invention provides rather use verbal language, images, symbols, tactile perceivable funds, etc., transmitting exact or similar semantic meaning.

In�edenia can be carried out if necessary or desired, for example, once a month, once a week or every day, including several times a day, for example, at least once a day, from one to about forty times a day, from one to about thirty times a day, from one to about twenty times a day, from one to about fifteen times a day, from one to about ten times per day, from about two to about four times daily, or about three times a day.

The quantity of injected liquid composition may depend on various factors, including the General health of the mammal, age, gender, weight or the severity of the symptoms.

Liquid compositions of the present invention

In one embodiment, the liquid composition of the present invention include: 1) a thickener; 2) optionally, mucoadhesive polymer; and 3) nematalosa cooling substance.

In one embodiment, the composition is a non-Newtonian liquid, which demonstrates the value of the viscosity at zero shear from about 100 CPS (CP) to about 1000000 SP, from about 100 CPS to about 500000 SP, from about 100 CP to about 100,000 SP, from about 100 CPS to about 50000 CPS, from about 200 CP to about 20,000 CPS, from about 600 CP to about 20,000 CPS, from about 1000 to about 10000 CPS at a temperature of 37±1°C, when measured in accordance with the method of determining the shear viscosity, �written below. The composition can exhibit desirable characteristics for dosing, such as fluidity, precision, low dose and residue on the Cup, the ability to liquefaction if swallowed and may upon termination of shear stress, providing extended contact time to form a coating and long-lasting and immediate cooling action. It is believed that there is a synergy that is associated with the density of the product due to the effects of entanglement of polymer chains and nematologia cooling substances to provide longer cooling sensation.

In one embodiment, the liquid composition has a pH from about 1 to about 7, from about 2 to about 6.5, and from about 4 to about 6.

Thickener

The liquid composition of the present invention may contain a thickener. In the case of his presence, the composition contains from about 0.01% to about 10% thickener, alternatively, from about 0.02% to about 5%, alternatively, from about 0.03% to about 4%, alternatively, from about 0.04% and about 3%, alternatively, from about 0.05% to about 1% of thickener by weight of the composition.

Non-limiting examples of thickeners include xanthan gum, cellulose polymers such as carboxymethylcellulose (CMC), hydroxyethylcellulose, hydroxymethylcellulose and hydroxy�mobilecellular, carrageenan, polyacrylic acid, crosslinked polyacrylic acid such as Carbopol®, polycarbophil, alginate, clay, and combinations thereof. In one embodiment, the thickener is a xanthan gum.

Mucoadhesive polymer

The liquid composition of the present invention may contain mucoadhesive polymer. In the case of his presence, the composition contains from about 0.01% to about 10% mucoadhesive polymer, alternatively, from about 0.02% to about 5%, alternatively, from about 0.03% to about 4%, alternatively, from about 0.04% and about 3%, alternatively, from about 0.05% to about 3%, by weight of the composition.

Non-limiting examples mucoadhesive polymer include polyvinylpyrrolidone (povidone), copolymers of methyl vinyl ether and maleic anhydride (Gantrez®), guar gum, tragacanth gum, Polydextrose, cationic polymers, poly(ethylene oxide), poly(ethylene glycol), poly(vinyl alcohol), poly(acrylic acid), crosslinked polyacrylic acid such as Carbopol®, polycarbophil, poly(hydroxyethylmethacrylate), chitosan, cellulose polymers such as carboxymethylcellulose (CMC), hydroxyethylcellulose, hydroxymethylcellulose, hydroxypropylmethyl cellulose, and combinations thereof. In one embodiment, mucoadhesive polymer is a polyvinylpyrrolidone.

Nematolosa cooling substance

The liquid composition of the present invention may contain nematolosa cooling substance. Nematolosa cooling substance is menthol, however, nematology cooling substances may contain structural modification of menthol. It is desirable that a cooling substance possessed the characteristic odor or taste, at the same time providing a cooling sensation increased duration, so that the effect could be seen for a considerable period of time after contact with the mucous membrane of the oral cavity, e.g., within at least 10 minutes, alternatively, more than 20 minutes after injection, an alternative, more 30 minutes after injection, an alternative, more 45 minutes after injection, an alternative, more than 60 minutes after injection.

In the case of his presence, the composition contains from about 0,00001% to about 2% nematologia cooling substances, alternatively, from about 0,00005% to about 1%, alternatively, from about 0,001% to about 1%, alternatively, from about 0,001% to about 0.5%, alternatively, from about 0,001% to about 0.03% of nematologia cooling of a substance, by weight of the composition.

Non-limiting examples nematology cooling substances include entepicondylar (for example, supplied under the name Frescolat® MGA by the company Haarmann & Reier), N-(4-cyanomethylene)-p-metacarbonate or N-(4-cyanomethylene)-5-methyl-2-(1-methylethyl)cyclohexanecarboxylic (e.g., commercially available from the company Givaudan), N-(2-(pyridin-2-yl)ethyl-3-p-metacarbonate (e.g., commercially available from the company Givaudan), N-(4-sulfamoylbenzoyl)-p-metacarbonate, N-(4-cyanophenyl)-p-metacarbonate, N-(4-acetylphenyl)-p-metacarbonate, N-(4-hydroxymethylene)-p-metacarbonate, M-(3-hydroxy-4-methoxyphenyl)-p-metacarbonate, 2-isopropyl-N, 2,3-trimethylbutyramide (for example, known as WS-23); N-ethyl-p-Mentana-3-carboxamide (for example, known as WS-3); ethyl-3-(p-Mentana-3-carboxamido)acetate (for example, known as WS-5), mantellato (for example, commercially available as Frescolat® ML from the firm Haarmann & Reimer), methoxypropane-1,2-diol (for example, commercially available as Coolant Agent 10 from the company Takasago International), p-Mentana-3,8-diol (for example, commercially available as PMD38) - Takasago International, isopulegol (for example, commercially available under the name "Coolact P®" from the company Takasago International), (1R,2S,5R)-2-isopropyl-5-methyl-N-(2-(pyridin-2-yl)ethylcyclohexylamine, (1-glycerol-p-Mentana-3-carboxylate), (a glycol-p-methane-3-carboxylate), (N-t-butyl-p-Mentana-3-carboxamide), N-(4-ethoxyphenyl)-p-Mentana-3-carboxamide), 3-(1-menthoxy)propane-1,2-diol, 3-(1-menthoxy)-2-methylpropan-1,2-diol, methylpyrrolidinyl) (for example, commercial DOS�upny as Questice®), (1R,3R,4S)-3-Menthyl-3,6-dioxaheptyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-methylmethacrylat (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-Menthyl-3,6,9-trioxadecyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)-Menthyl-11-hydroxy-3,6,9-trioxadecyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-Menthyl-(2-hydroxyethoxy)acetate (for example, commercially available from the company Firmenich), cubeba (e.g., commercially available from the company Firmenich), 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydropyrimidin-2-he), 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone (for example, known as Icilin or AG-3-5), Mantellate, metaglidasen, L-monomethylamine, L-monomethylester, 3-1-methoxypropane-1,2-diol (for example, known as Coolact 10), 2-1-methoxyethanol (for example, known as Cooltact 5) and mixtures thereof. Additional nematology cooling substances described in U.S. patent No. 7414152, US 20100086498 A1 and WO 2010/128026 A2. In one embodiment, nematolosa cooling the substance is a N-(4-cyanomethylene)-p-metacarbonate, including all 8 stereoisomers created 3 chiral, centre. In particular, [1R,2S,5R]-N-(4-cyanomethylene)-p-metacarbonate can be easily synthesized from natural 1-menthol.

Flavouring ingredient

Nematolosa cooling substance may be introduced into compositium the form of individual or purified chemical compounds or by adding flavoring ingredient such as natural oils or extracts. In one embodiment, such natural oils or extracts can be purified to remove components that are relatively unstable and can degrade and modify the desired profile of perception, leading to the formation of less acceptable from an organoleptic point of view of the product. In the case of their presence, flavoring ingredients generally used in the compositions in amounts comprising from about 0,001% to about 8%, by weight of the composition. Non-limiting examples include EverCool™ 180, available from the company Givaudan (Cincinnati, OH), which is supplied, for example, in the form of a 5% solution of M-(4-cyanomethylene)-p-metacarbonate ingredient in taste cool white grape (white grape with a cooling effect) or in the form of a 7.5% solution of M-(4-cyanomethylene)-p-metacarbonate in such a flavoring ingredient, curly mint or peppermint. Additional examples of flavoring ingredients include, without limitation, oil of peppermint, oil field mint, oil curly mint, Wintergreen oil, oil of flowers of the clove tree, Cassia, sage, Petrushenka oil, marjoram, lemon, lime, orange, cherry, CIS-jasmon, 2,5-dimethyl-4-hydroxy-3(2H)-furanone, 5-ethyl-3-hydroxy-4-methyl-2(5H)-furanone, vanilla, ethylvanillin, anisaldehyde, 3,4-methylenedioxybenzene, 3,4-dim�oxybenzaldehyde, 4-hydroxybenzaldehyde, 2-methoxybenzaldehyde, benzaldehyde; cinnamic aldehyde, hexylcaine aldehyde, alpha-medicority aldehyde, ortho-otoxicity aldehyde, alpha-acetocarmine aldehyde, propergate, heliotropine, 4-CIS-heptenal, diacetyl, methyl-p-tert-butylphenoxyacetyl, menthol, methyl salicylate, utililities, 1-methylacetate, Oksanen, alpha-irison, methylcinnamic, amylcinnamic, BUTYLCARBAMATE, ethylbutyrate, ethyl acetate, methylanthranilate, isoamyl acetate, isoamylamine, allylcapronate, eugenol, eucalyptol, thymol, cinnamic alcohol, octanol, octanol, decanol, decanal, generationy alcohol, benzyl alcohol, alpha-terpineol, linalool, limonene, citral, maltol, eternality, anethole, dihydroindol, carvone, menthone, β-damascenone, ionone, gamma-decalactone, gamma nonalactone, gamma undecalactone and mixtures thereof. Generally suitable flavoring ingredients are compounds containing structural features and functional groups, to a lesser extent prone to redox reactions. Such substances include derivatives flavoring chemical compounds which are saturated or contain a stable aromatic ring or ester group.

An additional component

The liquid composition may contain one or more additional components. In the case when�Ustia, the composition contains from about 0,00001% to about 30%, alternatively, from about 0,0001% to about 25%, alternatively, from about 0,001% to about 20%, alternatively, from about 0.01% to about 15%, alternatively, from about 0.1% to about 10%, alternatively, from about 1% to about 10% of additional components, by weight of the composition of additional components.

Non-limiting examples of additional components include cooling agents such as menthol, agents that create a feeling of warmth, flavoring agents, agents that cause salivation, tea extract, vitamin a, vitamin C, vitamin b, vitamin D, carotenoid, rosemary, rosemary extract, caffeic acid, coffee extract, turmeric extract, curcumin, blueberry extract, grape seed extract, rosmarinic acid, antioxidant, amino acid, enzyme, prebiotic, probiotic, Andrographis extract, I-tryptophan, garlic (Allium sativum), medicines made of herbs, vitamins, supplements, antioxidants, natural ingredients, minerals, energy ingredients, tools to improve sleep, means of enhancing the immune system, colorant, preservative, flavoring, flavouring substance, fruit extract, stimulator salivation, and combinations thereof.

Non-limiting examples of cooling agents include menthol, (1-glycerol-p-Mentana-3-�carboxylat) (e.g., known as WS-30), (a glycol-p-methane-3-carboxylate) (for example, known as WS-30), (N-t-butyl-p-Mentana-3-carboxamide) (for example, known as WS-14), (N-(4-ethoxyphenyl)-p-Mentana-3-carboxamide) (for example, known as WS-12), 3-(1-menthoxy)propane-1,2-diol, 3-(1-menthoxy)-2-methylpropan-1,2-diol, Menthyl-pyrrolidonecarboxylic (for example, commercially available as Questice®), (1R,3R,4S)-3-Menthyl-3,6-dioxaheptyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-methylmethacrylat (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-Menthyl-3,6,9-trioxadecyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)mental-11-hydroxy-3,6,9-trioxadecyl (e.g., commercially available from the company Firmenich), (1R,2S,5R)-3-Menthyl-(2-hydroxyethoxy)acetate (for example, commercially available from the company Firmenich), cubeba (e.g., commercially available from the company Firmenich), 1-[2-hydroxyphenyl]-4-[2-nitrophenyl]-1,2,3,6-tetrahydro-pyrimidine-2-it (example is known as icilin or AG-3-5), 4-methyl-3-(1-pyrrolidinyl)-2[5H]-furanone, Mantellate, liselilerin.html, peppermint oil, L-monomethylamine, L-monomethylester, 3-1-methoxypropane-1,2-diol (for example, known as Coolact 10) and 2-1-methoxyethanol (for example, known as Coolact 5).

Non-limiting examples of agents that create a feeling of warmth, include TK 1000, TK 1 MM, Heatenol (commercially available from the company Sensient Flavor, Optaheat (commercially available from the company Symrise Flavors), cinnamon, polyethylene glycol, capsicum, capsaicin, and curry.

Non-limiting examples of flavoring agents include natural flavouring agents, artificial flavoring agents, artificial extracts, natural extracts, and combinations thereof. Non-limiting examples of flavoring agents include vanilla, honey-lemon, lemon-honey, cherry-vanilla, peach, honey-ginger, chamomile, cherry, cherry cream, mint, vanilla-mint, dark berries (dark berry), BlackBerry, raspberry, peppermint, curly mint, honey-peach, acai berry (acai berry), cranberry, honey-cranberry, tropical fruit, pitaya (dragon fruit), Goji, mint Krasnoznamennaya (red stem), pomegranate, black current (black current), strawberry, lemon, lime, peach-ginger, orange, orange-cream, creamsicle, apricot, anethole, ginger, jackfruit (jack fruit), cannon (star fruit), blueberry, fruit punch, lemongrass, chamomile-lemongrass, lavender, banana, strawberry-banana, grapes, raspberries white-barked (blue raspberry), lemon-lime, coffee, espresso, cappuccino, honey, Wintergreen-mint, bubble-gum (bubble gum), sour (tart) honey-lemon, sour (sour) lemon, green Apple, boysenberry, rhubarb, strawberry-rhubarb, persimmon, green tea, black tea, red tea, white tea, honey-lime, cherry-lime, Apple, tangerine, grapefruit, kiwi, pear, vanilla, ethylvanillin, maltol, eternality, pumpkin, carrot cake, white chocolate-raspberry, chocolate, b�white chocolate, milk chocolate, dark chocolate, chocolate marshmallow, Apple pie, cinnamon, hazelnut, almond, cream, creme brulee, caramel, caramel nut, butter, butter toffee, caramel toffee, aloe Vera, whiskey, rum, cocoa, licorice, pineapple, guava, melon, watermelon, elderberries, mouth cooler, raspberries and cream, peach mango, tropical, cool berry, lemon ice, nectar, spicy nectar, tropical-mango, Apple-butter, peanut butter, tangerine, tangerine-lime, marshmallow, cotton candy, Apple cider, orange-chocolate, and mixtures thereof.

Non-limiting examples of agents that cause salivation, include compound of formula (I):

where R1represents C1-C2 n-alkyl; R2denotes 2-methyl-1-propyl and R3denotes hydrogen, or R2and R3together represent a fragment of formula -(CH2)n- where n is 4 or 5, or mixtures thereof.

In one embodiment, the agent that causes salivation, includes the material in which R2denotes 2-methyl-1-propyl and R3denotes hydrogen, more preferably where R1represents C1n-alkyl, R2denotes 2-methyl-1-propyl and R3denotes hydrogen. More preferably, the agent that causes salivation, includes the TRANS-pellitory, a chemical compound having a structure corresponding to �ormula (II):

The preferred form of vitamin C for use in the liquid composition is ascorbic acid or an equivalent salt of ascorbic acid or equivalent amount of a derivative of ascorbic acid. Vitamin C can be in the form of form immediate-release or forms with prolonged action.

Vitamin a and carotene can be obtained from animal or vegetable sources. Vitamin a could be in the form of vitamin A, retinol, retinilpalmitat, retinella, retailpoint, beta-carotene, alpha-carotene, beta-cryptoxanthin, and mixtures thereof.

Non-limiting examples of vitamin D include vitamin D3 (cholecalciferol), vitamin D2 (ergocalciferol) and their combinations. Additionally, non-limiting examples also include metabolites of vitamin D, including calcidiol, calcitriol, and combinations thereof. Vitamin D, including cholecalciferol, ergocalciferol, calcidiol and calcitriol may be obtained from synthetic or natural sources. Vitamin D, including cholecalciferol and calcitriol may be obtained from the extract of nightshade "nightshade" (Solanum glaucophyllum (malacoxylon)), tristinika yellowish (Trisetum flavescens) or cestrum day (Cestrum diurnum). Can be used as a pure vitamin D and/or the glycosides of vitamin D.

The tea extract is a polyphenol.Non-limiting examples of extracts include Camellia sinensis. Non-limiting sources tea extract for use in the present invention are black tea, white tea, half-fermented tea (Oolong) and/or green tea.

Another example of an additional ingredient is a probiotic. In the case of his presence, the liquid composition may contain from about 106up to 1012colony forming units (CFU) of the probiotic, alternatively, from about 106up to 1010SOME of the probiotic. Probiotic component can be lactic acid bacteria. In one embodiment, the probiotic is selected from the group consisting of bacteria of the genera Bacillus, Bacteroides, Bifidobacterium, Enterococcus (e.g., Enterococcus faecium), Lactobacillus and Leuconostoc, and combinations thereof. In another embodiment of the invention, the probiotic is selected from bacteria of the genera Bifidobacterium, Lactobacillus, and combinations thereof.

Non-limiting examples of lactic acid bacteria suitable for use in the present invention include strains of Streptococcus lactis, Streptococcus cremoris, Streptococcus diacetylactis, Streptococcus thermophilus, Lactobacillus bulgaricus, Lactobacillus acidophilus (e.g., the strain Lactobacillus acidophilus), Lactobacillus helveticus, Lactobacillus bifidus, Lactobacillus casei, Lactobacillus lactis, Lactobacillus plantarum, Lactobacillus rhamnosus, Lactobacillus delbruekii, Lactobacillus thermophilus, Lactobacillus fermentii, Lactobacillus salivarius, Lactobacillus reuteri, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium bifidum, Bifidobacterium animalis, Bifidobacterium pseudolongum, and Pediococcus cerevisiae, or mixtures thereof, preferably Lactobacillus salivariu, Bifidobacterium infantis, or mixtures thereof.

Suitable for use prebiotics include beet pulp, carob, psyllium, citrus pectin, rice bran, Constantinople pod, FOS, inulin, oligofructose, galactooligosaccharide, citrus pulp, mannan oligosaccharides, arabinogalactan, lactosucrose, glucomannan, lactulose, Polydextrose, Apple pomace, tomato pomace, carrot pomace, Cassia gum, xanthan gum, gum, gum karaya, gum Talha (talha), gum Arabic, cellulose, hemicelluloses, cellulose ethers, lignin and combinations thereof.

Andrographis is another example of an ingredient for use according to the present invention. Used here the value, Andrographis is a plant of the genus Andrographis, including a limited number of species distributed mainly in Asia. Only a few of these species are medicinal plants. In one embodiment, the plant belongs to the species of Andrographis paniculata, which in Ayurvedic medicine can be called calmag (Kalmegh).

Coffee extract is a polyphenol. The main component of coffee extract is the caffeic acid. In the case of the presence of coffee extract, non-limiting sources of coffee extract include coffee, coffee beans, coffee beans and/or p�odes of the coffee tree. In the case of the presence of caffeic acid, non-limiting sources of caffeic acid include coffee beans, the fruit of the coffee tree, coffee, tea, berries, rosemary extract and/or grape extract.

Turmeric extract is a polyphenol. Turmeric extract is a spice, comprising as the main active compound curcumin. Curcumin is a biologically active polyphenolic plant pigment. Non-limiting source of turmeric extract for use in the present invention is turmeric.

Bilberry extract is a polyphenol. Bilberry extract is rich in anthocyanins exhibiting antioxidant activity.

Grape seed extract is a polyphenol. Grape seed extract is rich in procyanidins, exhibiting antioxidant activity. Non-limiting source of grape seed extract for use in the present invention are grape seeds.

As carotenoids are a class of pigments that are present in the tissues of higher plants, algae, bacteria and fungi. They usually have color from yellow to dark red. In the case of the presence of carotenoid, it is chosen from the group consisting of beta-carotene, lutein, astaxanthin, zeaxanthin, bixin, lycopene and mixtures thereof./p>

Amino acids are the "building blocks" of the body. In addition to build cells and repair tissue, they form antibodies to combat invasive bacteria and viruses; they are part of the enzyme and hormonal system; they carry oxygen throughout the body and participate in muscle activity. In the case of the presence of amino acids, amino acids selected from the group consisting of lysine, taurine, histidine, carnosine, alanine, cysteine and mixtures thereof.

In the case of the presence of the antioxidant may be selected from the group consisting of vitamin E, CoQ10 (coenzyme Q10) and their mixtures. Main food sources of vitamin E are vegetable oils, margarine and cooking fat, and additional sources are nuts, seeds, whole grains and wheat germ. "Vitamin E" includes eight different chemical forms: four Tocopherols and four tocotrienols. The most biologically active form of vitamin E is alpha-tocopherol.

Non-limiting examples of preservatives include, without limitation, benzalkonium chloride, EDTA (EDTA), benzyl alcohol, sorbic acid, potassium sorbate, parabens, benzoic acid, citric acid, sodium benzoate and mixtures thereof.

Sweeteners

The liquid composition may contain a sweetener to provide sweetness and to give a certain consistent�and and density. Can be used natural or artificial sweeteners. Non-limiting examples of artificial sweeteners selected from the group consisting of sodium saccharin, Acesulfame potassium, Sucralose, aspartame, monoamine of DGL, neohesperidine of dihydrochalcone, thaumatin, neotame, cyclamates, stevia and mixtures thereof. Usually, these artificial sweeteners to use for sweetening liquid compositions are solids.

In the presence of a sweetener in a liquid composition, the liquid composition may contain from about 0,0001% to about 40% of the sweetener, from about 0,0001% to about 20% sweetener, alternatively, from about 0,0001% to about 10% sweetener, alternatively, from about 0,0001% to about 2% sweetener, and alternatively, from about 0.05% to about 1% of the sweetener, where all values are by weight of the liquid composition. Sweeteners can be artificial sweeteners.

In the presence of artificial flavoring, the liquid composition may contain from about 0,0001% to about 5% artificial sweetener, from about 0,0001% to about 3.5% artificial sweetener, alternatively, from about 0,0001% to about 2.0 percent artificial sweetener, alternatively, from about 0,0001% to about 1.0% of an artificial sweetener, � alternative, from about 0.05% to about 1.0% of an artificial sweetener, where all values are by weight of the liquid composition.

Optional ingredients

Liquid compositions may contain a wide range of optional ingredients. Non-limiting examples of optional ingredients include antimicrobial metal salts, optionally, means of enhancing the feeling of softness, optionally, stabilizers, abrasives, biological additives, chemical additives, chelating substances, denaturing means, astringent medicines (drug astringents, excipient, emulsifying agents, local analgesics, film formers, fragrance compounds, humectants, agents to impart opacity, plasticizers, propellants, reducing agents, solvents, blowing agents, stabilizers, hidroterapia substances soljubilizatory, suspendresume agents (non-surfactant), solvents agents for increasing the viscosity (aqueous and nonaqueous), sekwestrantov, buffers, keratolytics, and the like, and combinations thereof. Non-limiting examples of antimicrobial metal salts include zinc, iron, copper, silver, tin, bismuth, and combinations thereof. Non-limiting examples of excipients include sorbitol, maltitol, mannitol and combinations thereof. Unless otherwise indicated, the liquid compositions may optionally contain one Il� a few of these optional ingredients in concentrations constituting from about 0,001% to about 99%, alternatively, from about 0.01% to about 80%, alternatively, from about 0.01% to about 50%, alternatively, from about 0.01% to about 10%, where all values are by weight of the liquid composition.

Active ingredients

The liquid composition may further contain a wide variety of respiratory active ingredients suitable for the treatment of respiratory symptoms. Non-limiting examples include analgesics, anticholinergics, antihistamines, anti-inflammatories, antipyretics, antitussives, protivostoyanie funds, expectorants, mucolytics, antiviral agents, and combinations thereof.

Examples protivozastojnye funds include: phenylephrine, naphazoline, 1-desoxyephedrine, ephedrine, propylhexedrine and pseudoephedrine. Examples of anticholinergic drugs include ipratropium, chlorpheniramine, brompheniramine, diphenhydramine, doxylamine, clemastine and triprolidine. Conventional analgesics, anti-inflammatories, and antipyretics include: ibuprofen, Ketoprofen, diclofenac, naproxen, acetaminophen and aspirin. Examples of antiviral agents include: amantadine, rimantidine, pleconaril, zanamivir and oseltamivir. Examples of antitussives include codeine, dextromethorphan, chlophedianol and �levodropropizine. Examples of expectorants include guaifenesin. Examples of mucolytics include Ambroxol and N-acetylcysteine. Examples of antihistamines include diphenhydramine, doxylamine, triprolidine, clemastine, Pheniramine, chlorpheniramine, brompheniramine, dexbrompheniramine, loratadine, cetirizine and Fexofenadine, levocetirizine, desloratidine, amlexanox, alkylamine derivatives, cromolyn sodium, acrivastine, ibudilast, bamipine, ketotifen, nedocromil, omalizumab, dimetindene, oxatomide, pemirolast, pyrobitumen, pentigetide, analgin, ecumest, Taprobane, ramatroban, triprolidine, repirinast, suplatast of tosylate aminoacylase esters, casinolist, bromodiphenhydramine, tranilast, carbinoxamine, traxex, chlorphenoxamine, diphenylpyraline, Embraer, p-methyldiphenylamine, moccasin, orphenadrine, phenyltoloxamine, setaction, derivatives of ethylene diamine, chloropyramine, chlorate, methapyrilene, pyrilamine, falastin, terdiman, thonzylamine hydrochloride, tripelennamine, piperazines, chlorcyclizine, clientin, homochlorcyclizine, hydroxizin, tricyclic compounds, phenothiazines, mequitazine, promethazine, thiazinamium metilsulfate, other tricyclic compounds, azatadine, cyproheptadine, deptropine, isothipendyl, olopatadine, rupatadine, antazoline, astemizole, azelastine, bepotastine, klemizol, elastin, emedastine, epinastine, �evocable, mebhydrolin, mizolastine, phenindamine, terfenadine, tritoqualine.

The liquid composition may contain an amount of active ingredient in the range of values from 0% to about 15%, alternatively, from 0.0001% to about 10%, alternatively, from about 0,001% to about 7%, and alternatively, from about 0.01% to about 5%, where all values are by weight of the liquid composition.

A method of manufacturing

Liquid compositions can be manufactured by any known or otherwise effective methods suitable for the preparation of a composition that provides a therapeutic benefit. In one embodiment, only for illustrative purposes, respiratory active ingredients, flavoring substances, nematology cooling substances and other cooling agents is dissolved in the glycols and ethanol. Separately, mucoadhesive polymers and/or thickening agents are added to water in such a way as to avoid clumping and the formation of partially hydrated particles of the thickener, commonly called "fish eye". After thickening the mixture, add and dissolve water-soluble ingredients, such as buffers, dyes, sweeteners and preservatives. Glycol-ethanol premix is then added to the aqueous phase mucoadhesive polymers and/or thickeners. At the end add liquid products, such as corn syrup, high soda�gether fructose, a solution of sugar, sorbitol and/or glycerol, and the mixture was stirred until a homogeneous state. The composition is then packaged in suitable containers, for example, polyethylene terephthalate bottles.

Sets

In an additional embodiment, the invention may provide for a set. The set can include: delivery device and a liquid composition contained in the device to be transported; wherein the liquid composition comprises a thickener; mucoadhesive polymer; and nematolosa cooling substance, and wherein the liquid composition creates an overall cooling sensation. The kit may further comprise at least one additional component. The kit may further comprise at least one optional ingredient. The kit may also contain additional liquid composition in a standard amount, such as a sample or in both versions. The kit may further contain additional composition which is set with a liquid composition contained in the device for delivery, or attached to the outside of the device for delivery. For example, if the liquid composition contained in the device to deliver, is a fluid composition to create a long lasting cooling sensation, additional composition and/or liquid composition may be intended for ingestion. T�activate, if the liquid composition in the device for delivery is a liquid composition for the relief of sore throat, additional liquid composition or the composition may be intended for the treatment of watery nasal discharge, nasal congestion or stagnation in the chest, sneezing, pressure, headache, pains (aches), fever. Also, if the liquid composition in the device for delivery is a liquid composition intended for providing a cushioning effect in persons experiencing cold symptoms, additional liquid composition and/or composition may be a vitamin. The kit can also contain a cleaning cloth for vysmarkivaniya in combination with a liquid composition, a disinfectant for the hands in combination with the liquid composition, or grooming kit in the daytime or grooming kit at night, depending on the additional liquid composition, an additional ingredient and/or optional ingredients, combined with the liquid composition. The kit may further comprise a coupon, a discount coupon or an advertisement. The kit may further contain instructions. Such instructions may also include illustrations.

Experimental studies

Experimental studies include assessment of liquid compositions 391, 428, 337 and 215 with Muko�designee polymers and/or coagulants or without mucoadhesive polymers and/or thickeners and nematology cooling substances or without in comparison with the liquid composition with 672 mucoadhesive polymers and thickeners and nematology (non-methanol) a cooling substance, and additionally in comparison with a liquid composition 723, not containing mucoadhesive polymers, thickeners, and containing nematology cooling substances, to determine the contribution of each variable in objective differences in opacity, a cooling step, the density of the product, a cooling sensation and soothing abilities, with the help of expert descriptive sensory panel (descriptive sensory panel). The panel will assess the full battery of questions, typically used for descriptive panel.

The group of experts (n=11, trained by the method of descriptive analysis Spectrum™) adhered to the standard evaluation Protocol compositions respiratory products (to draw in a small amount of product across the lips for the evaluation of the density of the product, then completely swallow the sample and estimate the rest of the studied attributes) for a given liquid compositions in completely blind and randomized consecutive tests without comparison (sequential monadic) (6 products according to the scheme of the Latin square). Not included in the expert group of technicians give 30 ml of the compositions in closed caps the souffle cups 110 g (4 oz.), marked only three-digit mask code in �word standard fluorescent lighting and when the ambient temperature is 20-21°C (70-72°F). Key analyze sensory attributes include: density of the product (only in the initial moment of time), feeling cold in your mouth, feeling cold in the throat, a cooling sensation and soothing effect. All attributes are measured immediately after swallowing and (except density) at the following time points after swallowing: 5, 10, 20, 30, 45 and 60 minutes. Between the testing of samples withstand a minimum clearance of time equal to 2 hours. All attributes were measured on a scale of 0-60 intervals in polednice. More specifically, there were tested the following products:

Propylene glycol4,08254,12884,08674,12464,13334,0881
Povidone K901,02060,00001,02170,00000,00001,0220
Sodium citrate dehydrate0,40480,40940,40520,40900,40980,403
Nematology cooling substances*0,05100,05200,05100,05200,01000,0000
Flavoring0,27050,27310,27080,27280,20700,1840
Saccharin sodium0,20410,20640,20430,20620,20670,2044
Citric acid0,15270,15440,15280,15430,15460,1529
Xanthan gum0,10210,00000,00000,10310,00000,1022
Sodium benzoate0,10210,1032Is 0.102 0,10310,10330,1022
PEG-40 stearate0,05100,05160,05110,05160,05170,0511
FD&C red # 400,04350,04400,04350,04390,04400,0435
FD&C blue No. 10,00010,00010,00010,00010,00010,0001
Total100,0000100,0000100,0000100,0000100,0000100,0000
* The levels nematology cooling substances: 672, 391, 428, 337 contain 0,015% WS-3, 0,035% EverCool™ 180; 723 contains 0.01% WS-3; EverCool™ 180 shipped firm Givaudan (Cincinnati, OH) in a 5% solution of N-(4-cyanomethylene)-p-metacarbonate ingredient in taste cool white grape (white wine�grad with a cooling effect).

Method of preparing compositions

To 672, 215:

Slowly add the povidone to the water and stirred until dissolved. Add citrate buffer, sodium saccharin, sodium benzoate and dyes to the water phase and stirred until dissolved. Cook glycol premix: combine glycols, ethyl alcohol, nematology cooling substances and flavoring. Add xanthan gum and mix until well dispersed state. Add glycol premix to an aqueous phase. Add corn syrup with high fructose. Add PEG-40 stearate and mix until dissolved and a homogeneous state of the mixture.

For 391, 723:

Add to water, citrate buffer, sodium saccharin, sodium benzoate and dyes and stirred until dissolved. Cook glycol premix: combine glycols, ethyl alcohol, nematology cooling substances and flavoring. Add glycol premix to an aqueous phase. Add corn syrup with high fructose. Add PEG-40 stearate and mix until dissolved and a homogeneous state of the mixture.

For 428:

Slowly add the povidone to the water and stirred until dissolved. Add citrate buffer, sodium saccharin, sodium benzoate and dyes to the water phase and stirred until dissolved. Cook glycol premix: combine�tween glycols, ethyl alcohol, nematology cooling substances and flavoring. Add glycol premix to an aqueous phase. Add corn syrup with high fructose. Add PEG-40 stearate and mix until dissolved and a homogeneous state of the mixture.

For 337:

Add citrate buffer, sodium saccharin, sodium benzoate and dyes to the water and stirred until dissolved. Cook glycol premix: combine glycols, ethyl alcohol, nematology cooling substances and flavoring. Add xanthan gum and mix until well dispersed state. Add glycol premix to an aqueous phase. Add corn syrup with high fructose. Add PEG-40 stearate and mix until dissolved and a homogeneous state of the mixture.

Results and conclusions

Sensory data, including the coverage, feeling cold, the density of the product, a cooling sensation and soothing effect, collected under these experimental studies show that the presence of nematologia cooling agents in combination with mucoadhesive polymers and/or thickening agents enhances sensory perception of several key attributes of liquid compositions. First, it adds mucoadhesive polymers and thickeners increase the degree of perceived density products�that retracting the sample through the lips, see Fig.1. Mucoadhesive polymers and thickeners together create the highest perceived thickness of the product, followed by the presence of only one of mucoadhesive polymers and/or thickeners, and then the composition 391 and 723, none of which contains a polymer. The addition nematologia cooling substances provides a stronger perceived sense of coldness in the mouth for formulations of the compositions, with the addition of one or both of the polymers leads to a stronger sense of cold in the mouth than in the absence of polymers, especially in the time period of 20-60 minutes after ingestion, see Fig.2. For a period of 10-45 minutes after ingestion, the addition of a thickening agent, one or in combination with mucoadhesive polymer, caused a strengthening of the perceived sensation of cold in the throat compared with the formulations of the compositions containing only mucoadhesive polymer or non-polymer, see Fig.3. The perception of a cooling sensation, no doubt, is enhanced by the addition of one or both thickening and/or mucoadhesive polymers - especially in a time period of 10-60 minutes after swallowing, see Fig.4. Of particular interest is the absence of enhancement of the perception of a chilly feeling in the time period from the time immediately after swallowing to 10 minutes after that only one m�coadhesion polymer, although in later times mucoadhesive polymer provides enhanced perception chilly sensations in comparison with the formulations of compositions that do not contain polymers. Finally, experimental (experiential) measured "softening effect" (as defined in the test as follows: "the Measure of perceived feelings of comfort/rest/ease, ranked as if you had a cold, sore throat or upper respiratory tract illness", see Fig.5) is amplified during the evaluation period by the addition of nematology cooling substances and has higher values in the presence of one or both of the materials from mucoadhesive polymer and/or a thickener.

The method for determining the shear viscosity

Liquid compositions having a viscosity which depends on the applied load or shear rate. Film flowing down the wall under the action of gravity, is a process controlled by the voltages. In the experimental determination of flow curve applied to the liquid stress increases, and for each voltage level is recorded, the observed viscosity. Since the liquid composition after intake will be at body temperature, measurement of flow curves is carried out at 38°C. For all tests using a rheometer AR-G2 company TA Instruments, equipped with� concentric cylinder of standard size DIN (Couette). The rotor has a diameter of 14 mm, and the stator has a diameter of 15 mm. Immersion probe length equal to 42 mm, and the clearance of 59.2 mm. After mounting fixture and install the tool to the zero position, approximately 13 ml of liquid composition is placed in a Cup viscometer flow (Couette cup), and then the measuring device is lowered into the liquid. After a short period of thermal equilibrium (2 minutes), the application program (THE Version 5.4.0) manages the tool, step increasing the applied voltage from 0.01 PA to 100 PA. Measure the viscosity and record on a logarithmic scale in the specified voltage range. These are typically in the form of a graph of viscosity versus shear stress. There are several theoretical models that can be used to approximate data. In the case of the investigated compositions to represent liquid compositions used models Ellis (Ellis). The viscosity at zero shear is determined by averaging the values of viscosity at low stress viscosity curve is the voltage, which is also called the Newtonian plateau (if it occurs).

Some materials may not have a plateau at low shear rates that is not possible to determine the viscosity at zero shear. In these cases, usually, a viscosity at opredelennosti shift. The value of the viscosity at zero shear is expressed in centipoise (CP).

EXAMPLES

The following examples further describe and demonstrate variations within the scope of the present invention. They are for illustration only and should not be construed as limiting the present invention.

Below are the various non-limiting examples of liquid compositions of the present invention.

Example 1Example 2Example 3Example 4Example 5Example 6Example 7
Ingredient% wt.% wt.% wt.% wt.% wt.% wt.% wt.
WaterQSQSQSQS QSQSQS
Corn syrup with high fructose (77%)21,12121,6220018
Polyethylene glycol 400141414140017
Sorbitol (70%)000013,113,10
Glycerin0000880
Ethyl alcohol (95%) 7,47,47,47,4008
Propylene glycol444423234
Acetaminophen2222222
Povidone K901100101
Gantrez® S97000,5000 0
Carbopol® 971000000,40
Sodium citrate dehydrate (dehydrate)0,40,40,40,40,200,4
Flavoring0,20,20,20,20,30,30,1
Menthol0,030,060,030,030,030,030,1
WS-30,020,02 0,020,020,020,020
Flavor with the taste of white grapes (EverCool™ 180)*0,040,06000,040,040,040,040,04
Saccharin sodium0,20,20,20,20,20,20,2
Citric acid0,150,150,150,150,20,00000,2
Xanthan gum0,10,10,10,10,10 0,1
Carrageenan0000,1000
Sodium benzoate0,10,10,10,10,10,10,1
Sodium hydroxide (20%)000000,10
Of dextromethorphan hydrobromide0,10,10,10,10,060,060,1
Dye FD&C0,040,04 0,040,040070070,04
PEG-40 stearate0,050,050,050,050,050,050,05
Of doxylamine succinate0,040,040,040,04000,04
Phenylephrine hydrochloride00000,030,030
* EverCool™ 180 shipped firm Givaudan (Cincinnati, OH) in 5% oastor N-(cyanomethylene)-p-metacarbonate ingredient in taste cool white grape (white grape with a cooling effect).

Examples 1 and 2 can be prepared by slowly Pribaltiyskaya povidone to water with vigorous stirring until dissolved. Then to the mixture with vigorous stirring slowly add xanthan gum and mix until until the mixture is clear and thickened. Add to the mixture, buffers, dyes, saccharin and sodium benzoate and stirred until dissolved. Separately, propylene glycol, polyethylene glycol, flavoring substances, cooling agents, nematology cooling substance and ethanol are combined in order to obtain a glycol premix. Acetaminophen, dextromethorphan hydrobromide and doxylamine succinate add glycol to the premix and mixed until dissolved. This glycol premix is then added to the aqueous phase and stirred until a homogeneous state. Add corn syrup with high fructose and stirred until a homogeneous state. Add PEG-40 stearate and mix until dissolved.

Example 3 can be prepared by slowly adding first Gantrez® and xanthan gum to water with vigorous stirring and mixing until then, until the mixture is clear and thickened. Then add to the mixture, buffers, dyes, saccharin and sodium benzoate and stirred until dissolved. Separately, propylene glycol, polyethylene glycol, flavoring substances, cooling agents, nematology cooling substance and ethanol are combined in order to obtain a glycol premix. The acetaminophen dextromethorphan hydrobromide and doxylamine succinate add glycol to the premix and mixed until dissolved. This glycol premix is then added to the aqueous phase and stirred until a homogeneous state. Add corn syrup with high fructose and stirred until a homogeneous state. Add PEG-40 stearate and mix until dissolved.

Example 4 can be prepared by slowly adding first carrageenan and xanthan gum to water with vigorous stirring and mixing until then, until the mixture is clear and thickened. Add to the mixture, buffers, dyes, saccharin and sodium benzoate and stirred until dissolved. Separately, propylene glycol, polyethylene glycol, flavoring substances, cooling agents, nematology cooling substance and ethanol are combined in order to obtain a glycol premix. Acetaminophen, dextromethorphan hydrobromide and doxylamine succinate add glycol to the premix and mixed until dissolved. This glycol premix is then added to the aqueous phase and stirred until a homogeneous state. Add corn syrup with high fructose and stirred until a homogeneous state. Add PEG-40 stearate and mix until dissolved.

Example 5 can be prepared by slowly adding first of povidone to water with vigorous stirring and mixing until dissolved. Then slowly add to mixture� xanthan gum with vigorous stirring and mixed until until the mixture is clear and thickened. Add to the mixture, buffers, dye, saccharin, sodium benzoate and phenylephrine and stirred until dissolved. Separately, propylene glycol, cooling agents, nematology cooling substance and ethanol are combined in order to obtain a glycol premix. Acetaminophen and dextromethorphan hydrobromide add glycol to the premix and mixed until dissolved. This glycol premix is then added to the aqueous phase and stirred until a homogeneous state. Add the sorbitol and glycerin and stirred until a homogeneous state. Add PEG-40 stearate and mix until dissolved.

Example 6 can be prepared by slowly adding first Carbopol® to water with vigorous stirring and mixing until dissolved. Was added slowly to a mixture of sodium hydroxide (20%) to neutralize/full thickening Carbopol®. Add to a mixture of sorbitol and glycerin and stirred until a homogeneous state. Add to the mix the dye, saccharin, sodium benzoate and phenylephrine and stirred until dissolved. Separately, propylene glycol, cooling agents, nematology cooling substance and ethanol are combined in order to obtain a glycol premix. Acetaminophen and dextromethorphan hydrobromide add glycol to the premix and mixed until dissolved. This glycolate� the premix is then added to the aqueous phase and stirred until a homogeneous state. Add PEG-40 stearate and mix until dissolved.

Example 7 is prepared in accordance with standard procedures, not necessarily in accordance with the procedures described above.

All the documents referred to in the detailed description of the invention, the relevant parts are included here as links; the designation of any document should not be construed as an admission that it is prior art against the present invention. To the extent that any meaning or definition of the term in this written document contradicts any meaning or definition of the term in a document incorporated by reference, should be considered dominant value or definition given to the term in this written document.

Although there have been illustrated and described a specific embodiment variants of the present invention, qualified specialists in this field will be understood that various changes and modifications can be made without going beyond the nature and scope of the invention. Thus, it is assumed that the appended claims cover all such changes and modifications within the scope of this invention.

1. Method therapy respiratory symptom in a mammal in need of such therapy, comprising stages, n� which: introducing a liquid composition, contains thickener, representing xanthan gum, and N-(4-cyanomethylene)-p-metacarbonate; and injected into the contact of the liquid composition to the mucosa of the oral cavity of a mammal, where the liquid composition is a non-Newtonian liquid having a viscosity at zero shear from about 600 to about 1000000 SP at a temperature of 37±1°C.

2. A method according to claim 1, characterized in that the composition contains from about 0.01% to about 10% of thickener by weight of the liquid composition.

3. A method according to claim 1, characterized in that the composition contains from about 0.05% to about 5% thickener by weight of the liquid composition.

4. A method according to claim 1, characterized in that the composition further includes mucoadhesive polymer selected from the group consisting of polyvinylpyrrolidone (povidone), copolymers of methyl vinyl ether and maleic anhydride, the guar gum, tragacanth gums, Polydextrose, cationic polymers, poly(ethylene oxide), poly(ethylene glycol), polyvinyl alcohol, poly(acrylic acid), crosslinked polyacrylic acid, polycarbophil, poly(hydroxyethylmethacrylate), chitosan, cellulose polymers and combinations thereof.

5. A method according to claim 4, characterized in that the composition contains from about 0.01% to about 10% mucoadhesive polymer by weight of the liquid composition.

6. Method �about p. 4, characterized in that the composition contains from about 0.05% to about 5% mucoadhesive polymer by weight of the liquid composition.

7. A method according to claim 4, characterized in that mucoadhesive polymer is a polyvinylpyrrolidone.

8. A method according to claim 1, characterized in that the liquid composition comprises from about 0,0005% to about 2.0% by N-(4-cyanomethylene)-p-metacarbonate from the weight of the liquid composition.

9. A method according to claim 1, characterized in that the liquid composition contains from about 0,001% to about 1% N-(4-cyanomethylene)-p-metacarbonate from the weight of the liquid composition.

10. Liquid composition for use in treating respiratory symptom in a mammal, containing the thickener, representing xanthan gum, and N-(4-cyanomethylene)-p-metacarbonate, wherein the liquid composition is a non-Newtonian liquid having a viscosity at zero shear from about 600 to about 1000000 SP at a temperature of 37±1°C.

11. The liquid composition according to claim 10, characterized in that it further comprises at least one additional component selected from the group consisting of tea extracts, vitamin A, vitamin C, vitamin b, vitamin D, carotenoids, rosemary, extracts of rosemary, caffeic acid, coffee extract, turmeric extract, curcumin, blueberry extract, extras�KTA grape seed, rosmarinic acid, antioxidants, amino acids, enzymes, prebiotics, probiotics, extract of Andrographis, I-tryptophan, garlic (Allium sativum), herbal medicines, vitamins, supplements, antioxidants, natural ingredients, minerals, energy boosting ingredients, tools to improve sleep, of funds, strengthening the immune system, coloring agents, preservatives, flavoring agents, flavoring agents, fruit extract, stimulants of salivary flow, cooling agents, agents that cause a feeling of warmth, flavoring agents, agents that cause salivation, and combinations thereof.

12. The liquid composition according to claim 10, characterized in that it additionally contains an active ingredient selected from the group consisting of analgesics, anticholinergics, antihistamines, anti-inflammatory agents, antipyretics, antitussives, protivozastojnye funds, expectorants, mucolytics, and combinations thereof.

13. The liquid composition according to claim 12, characterized in that it further contains at least one ingredient selected from the group consisting of excipients, emulsifiers, local analgesics, film-forming compounds, fragrances, humectants, agents, giving the opacity, plasticizers, propellants, reducing agents, solvent�th, blowing agents, stabilizers, hydrotropic substances, solubilization, suspendida agents (no surfactants), solvents, agents that increase the viscosity (aqueous and non-aqueous), sequestrants, buffers, keratolytics, and combinations thereof.

14. Liquid composition for use in treating respiratory symptom in a mammal, containing mucoadhesive polymer, thickener, representing xanthan gum, and N-(4-cyanomethylene)-p-metacarbonate, wherein the liquid composition is a non-Newtonian liquid having a viscosity at zero shear from about 600 to about 1000000 SP at a temperature of 37±1°C.



 

Same patents:

FIELD: medicine.

SUBSTANCE: what is presented is a group of inventions; it involves a method for activating the health recovery of an involved respiratory epithelial cell an injury of which is related to cough, post-viral or -bacterial infection, acute/chronic bronchitis or chronic obstructive pulmonary disease (COPD) by administering a compound of formula and/or formula , a composition for the same application on the basis of the above compound, a respective method of treating an inflammatory respiratory condition, a pharmaceutical composition for treating the inflammatory respiratory condition, and using the compound of formula (1) and/or formula (2) for preparing the therapeutic agent for treating cough, post-viral or -bacterial, acute/chronic bronchitis or COPD.

EFFECT: health recovery of the respiratory cell for 48 hours as shown by sialylated glycoconjugates on its surface after treatment with influenza virus or bacterium neuraminidase, as well as reducing a rate of cough in guinea pigs sensitised with citric acid solution.

10 cl, 37 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: claimed group of inventions relates to medicine, namely to therapy, and deals with treatment of acute and chronic respiratory system diseases and cough syndrome accompanying said diseases. For this purpose pharmaceutical composition, containing activated-potentiated antibodies to bradykinin, morphine and histamine, is introduced.

EFFECT: efficient treatment of said diseases and pathological states is provided due to summation of anti-coughing, anti-inflammatory and anti-allergic action of composition components.

13 cl, 2 dwg, 4 ex, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: group of inventions refers to medicine, particularly to therapy, and concerns treating acute and chronic respiratory diseases and cough syndrome. That is ensured by administering a pharmaceutical composition containing activated potentiated antibodies to bradykinin, morphine and histamine.

EFFECT: invention provides the pronounced effect in infectious-inflammatory and allergic cough by the synergetic effect of the ingredients of the composition.

4 cl, 4 ex, 2 dwg, 5 tbl

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry and represents an agent consisting of theobromine and a non-opiate antitussive agent representing an NMDA antagonist in the form of a combination preparation for treating cough.

EFFECT: invention provides a synergetic effect on cough suppression and improved clinical effectiveness in cough treatment.

20 cl, 1 dwg

FIELD: biotechnologies.

SUBSTANCE: invention refers to ligands in the form of synthetic peptide amides of a kappa-opiate receptor, and namely to agonists of the kappa-opiate receptor, which show a low inhibition degree of P450 CYP and a low degree of penetration into brain. According to the invention, synthetic peptide amide is described by the following formula:

EFFECT: pharmaceutical compositions containing the above compounds are suitable for prophylaxis and curing of pain and inflammation, which are related to different diseases and states.

19 cl, 11 dwg, 53 ex

FIELD: biotechnologies.

SUBSTANCE: invention refers to synthetic peptide amides of formula I

, which are agonists of a kappa-opiate receptor and show a low inhibition degree P450 CYP and lower brain penetration degree. Besides, the invention refers to pharmaceutical compositions containing the above compounds.

EFFECT: possibility of using compounds for prophylaxis and curing of pain and inflammation, which are related to different diseases and states.

17 cl, 9 tbl, 8 dwg, 39 ex

FIELD: chemistry.

SUBSTANCE: invention relates to a method for synthesis of moguisteine, which is an ethyl ether of (R,S)-3-[2-[(2-methoxyphenoxy)methyl]-1,3-thiazolidin-3-yl]-3-oxypropionic acid, involving a) reaction of guaiacol with 2-X-methyl-1,3-dioxolane to obtain 2-[(2-methoxyphenoxy)methyl]-1,3-dioxolane, b) reaction with cysteaminein the presence of an acid to obtain (R,S)-2-[(2- methoxyphenoxy)methyl]-1,3- thiazolidine, c) reaction with monoethylmalonic acid or a salt thereof in the presence of a condensing agent to obtain moguisteine.

EFFECT: obtaining moguisteine with high output and purity.

18 cl, 59 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to a preparation having an effect on air passages, relieving coughing in a human and containing: 0.01%-40% of a polyethylene oxide film-forming agent; 0.01%-15% of a gelling material specific in sodium carboxymethyl cellulose, carboxymethyl cellulose and their mixture; and a number of excipients.

EFFECT: preparation is packed in spray bottles; it contains no active pharmaceutical substance, provides cough relief after 20 min after the use and as often as necessary.

4 cl, 13 dwg, 27 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to pharmaceutical industry, particularly an antitussive and expectorant drug. The antitussive and expectorant composition containing the extract Coptidis rhizoma as an active ingredients wherein the extract represents a crude extract which is prepared by the use of one or more solvents specified in a group consisting of water and linear or branched alcohol having 1 to 4 carbon atoms as an extractant, or a solvent-soluble extract which is produced by adding an aqueous solution of linear or branched alcohol having 1 to 6 carbon atoms to the crude extract. The composition for treating a respiratory disease containing the antitussive and expectorant composition. A healthy functional foodstuff for relieving the respiratory disease containing the composition containing the extract Coptidis rhizoma as an active ingredient.

EFFECT: compositions and functional foodstuff are effective as the antitussive and expectorant composition.

8 cl, 5 dwg, 20 tbl, 6 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to otorhinolaryngology, and may be applicable for treating patients with angina acuta (acute tonsillitis). For this purpose, with underlying three daily oral introductions of mexidol (emoxipine succinate) 0.125 g in tablets and single daily oral introduction of D3 vitamin 4000 IU (100 mcg) and B12 vitamin 200 mcg, sequential gargarism with 0.1% hydrogen peroxide 15 minutes later followed by another gargarism with 0.125% Novocaine in 0.5% sodium thiosulphate. The gargarisms are applied 3-4 times a gay, each procedure lasts for 2-3 minutes. The therapeutic course makes 3-4 days, the therapy starts at least 24 hours before the symptom manifestation.

EFFECT: method provides higher clinical effectiveness ensured by fast arrest of clinical manifestations of the disease and intoxication syndrome, drastic reduction of viral and bacterial carrier state, arrest of the dysbiotic states of tonsils due to enabled prophage induction in lysogenic pathogenic microorganisms, antiviral action by interferon induction, non-resident microflora vegetation inhibition and symbiontic microorganism growth stimulation on the tonsil surface, free-radical oxidation inhibition in the biological media.

6 tbl

FIELD: medicine.

SUBSTANCE: treating tonsillopharyngitis in children is ensured by Panavir Inlight spray gel 1 oropharyngeal irrigation 2 times a day after meal daily for 5 days.

EFFECT: method enables treating more effectively by the anti-viral and cytoprotective action of the preparation, reducing a toxic load with no complications and applicability.

4 ex

FIELD: medicine.

SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.

EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.

3 cl, 2 tbl, 1 ex

FIELD: medicine.

SUBSTANCE: palatal tonsils are daily sanitated with antibacterial preparations selected in accordance with the bacteriological examination of oral smears for pathogenic microflora and antibiotic sensitivity with the tonsil lacunae washed for 10 days. Pre-anaesthesia is followed by the tonsil lacunae exposure to an ultrasonic disintegrator at a depth of a probe working area at an amplitude of 23-26 mc every second day for 5 days. That is followed by paratonsil administration of polyoxidonium in an adult dose of 6 mg every second day for 5 days; the therapeutic course is performed once a year.

EFFECT: method enables higher clinical effectiveness in chronic tonsillitis.

2 tbl, 2 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention relates to a composition for treating throat pain in the form of dispersible tablets. The claimed composition contains an endothermic cooling substance, representing xylitol, in an amount of 1-10 wt/wt % and an active substance, which contains menthol and 2,4-dichlorobenzyl alcohol and amylmetacresole.

EFFECT: invention ensures relief of symptoms, associated with throat pain, and ensures a cooling effect.

5 cl, 1 tbl

FIELD: medicine.

SUBSTANCE: method involves drug and irrigation therapy, laser therapy covering a sub-mandibular region; the novel is that drug therapy represents administering the hydrogel sterile material 'Coletex-gel-DNK-L' or 'Coletex-gel-ADL' 1-3 ml into each tonsil lacunas. Laser therapy additionally covers a projection of the common carotid artery, the carotid sinus, internal and external jugulars, the vagus nerve and the upper cervical sympathetic ganglion; these regions and the sub-mandibular region are pre-coated with the sterile textile tissue 'Coletex-AND' or 'Coletex ADL'. The exposure is performed in the infrared band series from both sides at a frequency of 1000 to 1500 Hz, output power 10 to 20 mW, length of exposure 2 to 8 min; after the procedure, the used tissue is left for 6-8 hours; the course consists of 3-10 daily procedures.

EFFECT: sequence of therapeutic procedures enables regaining a structural balance of the immune regulation that provides the central determination of eliminating the immunological reactivity disorders specific for children suffering chronic tonsillitis, eliminating manifested autonomic nervous system imbalance, providing the higher clinical effectiveness.

FIELD: medicine.

SUBSTANCE: starch or sorbite photosensitiser powder is administered into a laryngeal pharynx that is further exposed to laser light. The laser light exposure is performed at wave length 0.685 mcm, powder 18-20 mWt, energy density 18-28.8 J/cm2.

EFFECT: implementing the method provides the reliable laryngeal fixation of the photosensitiser, maintains the constant concentration of the photosensitiser for the whole therapeutic session, and thereby faster reduction of the inflammatory process.

2 cl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely otorhinolaryngology, phoniatrics and physiotherapy and may be used for the integrated treatment of aggravated chronic laryngitis. Starting from the 4-5th day from the aggravation, a standard drug therapy is additionally combined with an endolaryngeal injection of specific pyobacteriophague 1 ml and further exposure to low-frequency vibration covering 3 fields of the larynx and phonopaedic breathing exercises. The low-frequency vibration starts at a first filed comprising side neck surfaces at frequency 20 Hz per 1 filed with a vibratode advanced smoothly upward at 2-3 mm/sec with undisplaced skin and rectangularly up to a mandibular angle, and then downwards to a posterior triangle of neck for 1-2 minutes from each side; the patient does the phonopaedic breathing exercises and pronounces expiratory 'M'; that is followed by the vibrational exposure covering a projection of intersection of a thyroid cartilage plate and a border of sternocleidomastoid muscle (m.sternocleidomastoideus) at a thyroid cartilage notch at frequency 40 Hz and 60 Hz for 1-2 minutes from both sides according to the stable technique; the patient does the phonopaedic breathing exercises and pronounces expiratory vowels 'U', 'O', 'A'; that is followed by vibration of a collar at frequency 30-40 Hz with the vibratode advanced from a paravertebral line to a shoulder joint for 2-3 minutes from each side; the technique is labile. The course performs 8-10 combined daily procedures.

EFFECT: method enables higher clinical effectiveness ensured by the integrated effect on the patient's immune system in a combination with the drainage, anti-inflammatory, and trophic stimulating effects.

11 tbl, 2 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and aim at treating compensated non-specific chronic tonsillitis. A method involves a stress-protective therapy, a diet therapy, a vitamin therapy, a probiotic therapy, an antioxidant therapy, a therapy with prebiotic-like drugs, a local immunocorrecting and topical eradication therapy.

EFFECT: method is high effective in treating compensated non-specific chronic tonsillitis; it provides normalising an epigenetic regulation of gene expression and oxidation-reduction processes in the human body, creating conditions for relieving the micro-environmental disorder and recovering a colonisation resistance of the upper airway mucosa, an eradication of bacterial and viral infectious agents with underlying recovering an eubiosis of the upper airway mucosa, normalizing the gastrointestinal function, blocking the lipopolysaccharide effects of gram-negative bacteria, eliminating the aggravations within one year completely in the majority of patients.

9 tbl, 1 ex

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to medicine, namely to a method for preparing a therapeutic hydrogel material involving mixing an aqueous solution of sodium alginate and a drug preparation, dispersing a cross-linking agent that is presented by calcium sulphate in glycerol in the concentration of 0.8-2.5%, mixing the dispersion with the prepared mixture of sodium alginate with the drug preparation in ratio 1-2:4-6, placing the prepared product into a tiling pattern and keeping it till form-stable, conducting gamma sterilisation; the formation process involves the mechanical stability measurements with the diametral compression of the formed hydrogel; the hydrogel is considered to be formed once a thickness of the formed hydrogel varies with the diametral compression by 10-30%.

EFFECT: invention provides the wider medical variation of the drug concentrations, preparing high-thixotropy soft hydrogel materials (tablets) easy to administer, including through rectum, preparing the materials that preserve its all their physical-technical and mechanical properties after the gamma sterilisation along with the sterility.

4 cl, 10 ex

FIELD: veterinary.

SUBSTANCE: method involves the subcutaneous injections of donor animals' hyperimmune blood serum containing antihemagglutinin in titres to herpes virus-3 1:1280, to rednose virus - min. 1:256, to viral diarrhea -1:1024 and to adenovirus -1:128; in a dose of 2.0 ml/kg every 24 hours until recovered completely; besides, 20-30 minutes before feeding, a pytopreparation of 70% alcohol tincture of purple echinacea (Echinacea purpurea L) herb and blossom, common pine (Pinus sylvestris) buttons, horseheal (Inula helenium) roots and rhizomes, common licorice (Glycyrrhiza glabra L.) roots and harmala shrub (Peganum harmala) herb taken in relation 1:1:1:1:0.5 in the amount of 7-8% aqueous solution is administered in a dose of 3.0-3.5 ml/kg of body weight every 12 hours until recovered completely.

EFFECT: higher clinical effectiveness and natural body resistance.

4 tbl, 3 ex

FIELD: chemistry.

SUBSTANCE: disclosed are copolymers based on N-vinylpyrrolidone, having as terminal fragments a cyanovaleric acid residue and a hydrogen atom, having general formula (I) where the monomer link is a 4-vinylpyridine (4-VP) fragment, if X is or a 2-methyl-5-vinylpyridine (2-M-5-VP) fragment, if X is , wherein the content of monomer links which are 4-VP or 2-M-5-VP fragments is 20-90 mol%; the viscosity-average molecular weight Mµ of the copolymers is equal to 10-350 kDa, and the acid number is equal to (0.1-5.6)·10-3 mg KOH/g. Also disclosed is use of said copolymers as an anti-pneumoconiosis agent.

EFFECT: high efficiency of using the compound.

2 cl, 2 tbl, 11 ex

Up!